ACTRIMS 2022 | Developing novel biomarkers in MS: diagnostic, predictive, & prognostic

Jeffrey A. Cohen, MD, Cleveland Clinic, Cleveland, OH, comments on the common goals of researchers in the multiple sclerosis (MS) space; to develop quantitative, objective, and clinically useful biomarkers. Various types of biomarkers are under investigation to improve numerous aspects of MS diagnosis and management, including markers that can predict an individual’s risk of disease development, enable accurate disease monitoring, and give novel insights into disease processes. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.